Bioactive glass and autogenous bone as bone graft substitutes in benign bone tumors.
In a prospective randomized study, 25 patients with benign bone tumors were surgically treated with either bioactive glass S53P4 (BG) or autogenous bone (AB) as bone graft material. X-rays were taken preoperatively and postoperatively at 2 weeks and at 3, 8, 12, 18, 24, and 36 months. In addition, for most of the patients, CT scans were performed at the same time-points. No infections or material-related adverse reactions occurred in any patient. The filled cavity was replaced faster by new bone in the AB group than in the BG group (p = 0.0001). However, at 36 months, no statistical difference in cavity volume between the two groups was observed on X-rays (p = 0.7881) or on CT scans (p = 0.9117). In the BG group at 3 years, the filled cavity appeared, however, dense on X-rays, and glass granules on CT scans were observed. During the follow-up period, the cortical thickness seemed to increase more in the BG group than in the AB group (p < 0.0001).
Lindfors
Nina C
NC
Department of Orthopedic and Hand Surgery, Helsinki University Central Hospital, Helsinki University, Helsinki, Finland. nina.c.lindfors@hus.fi
Heikkilä
Jouni T
JT
Koski
Ilona
I
Mattila
Kimmo
K
Aho
Allan J
AJ
D001672:Biocompatible Materials; D001846:Bone Development; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000628:therapy*; D018786:Bone Substitutes; D005260:Female; D005898:Glass; D006801:Humans; D008297:Male; D014057:Tomography, X-Ray Computed
D001672:Biocompatible Materials; D018786:Bone Substitutes